FY2025 Earnings Estimate for Bruker Issued By Zacks Research

Bruker Co. (NASDAQ:BRKR - Free Report) - Investment analysts at Zacks Research lowered their FY2025 earnings per share (EPS) estimates for Bruker in a note issued to investors on Monday, February 10th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $2.73 per share for the year, down from their previous estimate of $2.76. The consensus estimate for Bruker's current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Bruker's Q4 2025 earnings at $0.92 EPS, Q4 2026 earnings at $0.84 EPS and FY2026 earnings at $3.32 EPS.

A number of other research analysts also recently issued reports on the company. Citigroup lowered their price target on Bruker from $80.00 to $75.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th. Bank of America upped their price target on Bruker from $78.00 to $80.00 and gave the company a "buy" rating in a report on Friday, December 13th. Wells Fargo & Company reduced their price objective on Bruker from $78.00 to $75.00 and set an "overweight" rating for the company in a research report on Wednesday, November 6th. TD Cowen reduced their price objective on Bruker from $72.00 to $70.00 and set a "hold" rating for the company in a research report on Wednesday, November 6th. Finally, UBS Group began coverage on Bruker in a research report on Tuesday, December 10th. They set a "neutral" rating and a $66.00 price objective for the company. Six analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $70.50.

Bruker Stock Performance

Shares of NASDAQ:BRKR traded down $1.11 during midday trading on Wednesday, reaching $50.04. 2,044,498 shares of the company's stock traded hands, compared to its average volume of 1,412,424. The company has a market cap of $7.59 billion, a price-to-earnings ratio of 24.06, a P/E/G ratio of 3.81 and a beta of 1.16. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.73 and a current ratio of 1.66. Bruker has a one year low of $48.07 and a one year high of $94.86. The stock has a 50 day moving average of $57.56 and a 200 day moving average of $60.59.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.52% and a net margin of 9.41%.

Institutional Trading of Bruker

Several institutional investors have recently made changes to their positions in BRKR. True Wealth Design LLC grew its position in shares of Bruker by 4,636.4% during the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company's stock worth $36,000 after purchasing an additional 510 shares in the last quarter. Eagle Bay Advisors LLC grew its position in shares of Bruker by 2,324.1% during the fourth quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company's stock worth $41,000 after purchasing an additional 674 shares in the last quarter. UMB Bank n.a. grew its position in shares of Bruker by 115.3% during the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company's stock worth $46,000 after purchasing an additional 354 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Bruker by 81.0% during the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company's stock worth $60,000 after purchasing an additional 388 shares in the last quarter. Finally, Values First Advisors Inc. purchased a new stake in shares of Bruker during the third quarter worth about $73,000. Hedge funds and other institutional investors own 79.52% of the company's stock.

Insiders Place Their Bets

In related news, CEO Frank H. Laukien purchased 100,000 shares of Bruker stock in a transaction on Monday, November 18th. The stock was acquired at an average price of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the transaction, the chief executive officer now directly owns 38,439,563 shares in the company, valued at $1,927,359,688.82. This represents a 0.26 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 28.30% of the company's stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.